Table of Contents

• Overview of Clinical Research
• Understanding (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE
• Trial Design and Methodology
• Target Patient Population
• Study Objectives and Endpoints
• Combination Treatment Approach

Overview of Clinical Research

Clinical trials investigating (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE represent an important area of research in the treatment of Alzheimer’s disease^[1]. The substance, referred to in clinical documentation as NSC001, is being evaluated for its potential to address cognitive and functional impairments associated with this progressive neurodegenerative disorder^[1].

The current phase of research focuses on establishing the safety profile and tolerability of (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE in patients diagnosed with mild to moderate Alzheimer’s disease^[1]. This represents a critical step in the drug development process, as understanding how patients respond to the treatment and whether they experience adverse effects is essential before larger-scale efficacy studies can be conducted.

Understanding (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE

In clinical trial documentation, (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE is identified as an orthosteric selective muscarinic M1 agonist^[1]. This designation indicates that the substance is designed to activate specific receptors in the brain that play important roles in memory and cognitive function.

The muscarinic M1 receptor is particularly abundant in brain regions involved in learning and memory, such as the hippocampus and cerebral cortex^[1]. In Alzheimer’s disease, there is a well-documented loss of function in the cholinergic system, which includes these receptors. By selectively targeting the M1 receptor subtype, (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE aims to potentially restore some of the lost cognitive function associated with this neurodegenerative condition.

Trial Design and Methodology

The clinical trial investigating (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE is structured as a Phase 2a, multi-center, randomized, parallel group, double-blind, and placebo-controlled study^[1]. Each of these design elements serves a specific purpose in ensuring the reliability and validity of the research findings.

The multi-center approach means the trial is being conducted at several different research facilities simultaneously^[1]. This design feature offers several advantages:

• Increased enrollment speed: Multiple sites can recruit participants simultaneously, allowing the study to reach its enrollment target more quickly
• Diverse patient population: Participants from different geographic locations and healthcare settings provide more representative data
• Enhanced generalizability: Results from multiple centers are more likely to apply to the broader patient population
• Reduced site-specific bias: Any unusual characteristics of a single research center are less likely to skew overall results

The randomized design ensures that participants are assigned to treatment groups by chance rather than by choice of researchers or patients^[1]. This randomization helps ensure that known and unknown factors that might influence outcomes are distributed evenly across treatment groups, allowing for fair comparison.

The double-blind methodology means that neither the participants nor the researchers administering the treatment know who is receiving (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE and who is receiving placebo^[1]. This design minimizes bias in how treatments are administered and how outcomes are assessed.

The parallel group structure indicates that different groups of participants receive different treatments simultaneously, with each participant remaining in their assigned treatment group throughout the study duration^[1]. This differs from crossover designs where participants switch treatments during the study.

The inclusion of a placebo control group is essential for determining whether any observed effects are truly due to (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE or might result from other factors such as natural disease progression, participant expectations, or increased medical attention^[1].

Target Patient Population

The clinical trial is specifically designed for individuals diagnosed with mild to moderate Alzheimer’s disease^[1]. This target population represents patients in the early to middle stages of the disease, where cognitive impairment is noticeable but patients retain some ability to perform daily activities.

The trial plans to enroll approximately 90 participants across all participating centers^[1]. This sample size is typical for Phase 2a trials, which aim to gather preliminary safety and efficacy data in a moderately sized group before proceeding to larger Phase 3 confirmatory trials.

Patients with mild to moderate Alzheimer’s disease typically experience:

• Memory difficulties: Problems remembering recent events, conversations, or appointments
• Cognitive challenges: Difficulty with problem-solving, planning, or organizing tasks
• Communication problems: Trouble finding words or following conversations
• Functional impairment: Increasing need for assistance with complex daily activities
• Behavioral changes: Mood changes, confusion, or disorientation

By focusing on this specific disease stage, the trial aims to evaluate whether (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE can benefit patients who still have substantial cognitive function to preserve^[1].

Study Objectives and Endpoints

The primary objective of the trial is to determine the safety and tolerability of (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE in participants with mild to moderate Alzheimer’s disease^[1]. This focus on safety is appropriate for a Phase 2a study, where understanding how patients respond to the treatment and identifying any adverse effects takes priority.

Safety assessments in this trial will likely include:

• Adverse event monitoring: Systematic recording of any unwanted symptoms or medical problems that occur during the study
• Laboratory tests: Regular blood and urine tests to monitor organ function and detect any treatment-related changes
• Vital signs: Measurement of blood pressure, heart rate, temperature, and respiratory rate
• Physical examinations: Regular medical assessments to detect any physical changes
• Electrocardiograms: Heart monitoring to ensure cardiac safety

Tolerability refers to how well patients can take the medication without experiencing unacceptable discomfort or side effects that would cause them to discontinue treatment^[1]. Good tolerability is essential for any medication intended for long-term use in chronic conditions like Alzheimer’s disease.

In addition to the primary safety objectives, the trial includes exploratory efficacy assessments^[1]. These exploratory endpoints are designed to provide initial signals about whether (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE shows promise for improving cognitive or functional outcomes in Alzheimer’s disease patients.

While the specific efficacy measures are not detailed in the available trial information, typical assessments in Alzheimer’s disease trials include:

• Cognitive function tests: Standardized assessments measuring memory, attention, language, and problem-solving abilities
• Functional ability scales: Evaluations of patients’ ability to perform daily activities
• Global assessments: Overall ratings of disease severity and change from baseline
• Behavioral measures: Assessment of neuropsychiatric symptoms such as agitation, depression, or apathy

Combination Treatment Approach

An important aspect of the trial design is that (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE is being evaluated both alone and in combination with trospium^[1]. This dual approach allows researchers to assess whether adding trospium affects the safety, tolerability, or efficacy profile of the primary treatment.

Trospium is a medication that blocks certain muscarinic receptors in the body, particularly those outside the central nervous system. Its inclusion in the trial design suggests that researchers are investigating whether combining it with (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE might help manage potential side effects that could occur from muscarinic receptor activation in peripheral tissues.

This combination strategy reflects a thoughtful approach to optimizing the therapeutic profile of (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE^[1]. By evaluating both monotherapy and combination therapy, the trial can provide valuable information about the best way to use this investigational treatment if it proves successful.

The trial’s status is listed as authorised, indicating that regulatory authorities have reviewed and approved the study protocol, and the trial is cleared to proceed with participant enrollment^[1]. This authorization represents an important milestone in the development of (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE as a potential treatment for Alzheimer’s disease.